Table 2 Effectiveness of guselkumab and adalimumab therapy measured through eight factors over 6 months

1M

3M

6M

p value (1M vs 0M)

p value (3M vs 0M)

p value (6M vs 0M)

PPPASI

5.3 (1.2, 14.0)

2.3 (0, 4.7)

0 (0, 2.6)

0.3828

0.0068*

0.0039*

SJ66

0 (0, 2.3)

0 (0, 1.5)

0 (0, 1.5)

0.0625

0.1563

0.1563

TJ68

3.0 (1.3, 5.5)

2.5 (1.0, 5.5)

2.5 (1.3, 5.5)

0.0898

0.0352*

0.0410*

PGA (cm)

3.6 (3.0, 4.7)

2.8 (1.3, 4.3)

3.3 (1.2, 3.9)

0.0039*

0.0171*

0.0225*

Pain VAS (cm)

3.4 (1.8, 4.8)

2.7 (1.3, 3.8)

1.8 (1.2, 3.6)

0.0273*

0.0176*

0.0137*

DAPSA

10.1 (5.6, 19.2)

9.3 (4.4, 18.7)

8.5 (4.8, 18.1)

0.0049*

0.0210*

0.0161*

HAQ

0.38 (0.13, 1.00)

0.19 (0, 0.69)

0.25 (0.03, 0.50)

0.0039*

0.0020*

0.0059*

EQ-5D

0.73 (0.56, 0.82)

0.73 (0.64, 0.85)

0.75 (0.64, 0.85)

0.1563

0.0391*

0.0488*

CRP (mg/dL)

0.09 (0.05, 0.22)

0.14 (0.04, 0.42)

0.07 (0.03, 0.35)

0.1204

0.1403

0.0775

1M

3M

6M

p value (1M vs 0M)

p value (3M vs 0M)

p value (6M vs 0M)

PPPASI

2.6 (1.1, 17.5)

1.2 (0.4, 15.6)

2.4 (0.4, 14.6)

0.2500

0.6523

0.5342

SJ66

0 (0, 1.0)

0 (0, 1.5)

0 (0, 1.5)

0.0547

0.2422

0.3750

TJ68

3.0 (1.0, 8.0)

1.0 (0, 5.0)

1.0 (0, 2.0)

0.0039*

0.0010*

0.0010*

PGA

2.2 (1.0, 4.1)

2.2 (1.1, 2.9)

2.2 (1.2, 3.9)

0.0059*

0.0068*

0.0195*

Pain VAS

2.5 (9.5, 3.8)

1.2 (0.8, 2.5)

1.0 (0.8, 1.9)

0.0103*

0.0039*

0.0039*

DAPSA

8.4 (6.1, 16.1)

6.5 (2.8, 12.2)

6.7 (3.2, 8.4)

0.0005*

0.0024*

0.0015*

HAQ

0.38 (0, 0.75)

0.38 (0, 0.63)

0.25 (0, 0.75)

0.0313*

0.0156*

0.0156*

EQ-5D

0.68 (0.65, 0.75)

0.68 (0.65, 0.77)

0.68 (0.66, 0.75)

0.0234*

0.0234*

0.0391*

CRP (mg/dL)

0.07 (0.01, 0.27)

0.10 (0.04, 0.30)

0.07 (0.02, 0.78)

0.0110*

0.1078

0.2077